All In Biotech

Drug Trial Radar · NCT04123613

Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)

A Multi-Center Open-label Investigation to Assess the Safety and Efficacy of Multiple Doses of DM199 in Patients With Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

84

Actual

Start

Dec 17, 2019

Primary completion

Mar 16, 2022

Study completion Mar 16, 2022

Sponsor

Lead sponsor
DiaMedica Therapeutics IncIndustry
Sponsor type
Industry
First posted
Oct 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, Phase II, multi-center study evaluating multiple doses of DM199 in participants with chronic kidney disease.

Conditions

  • Kidney Diseases

Interventions

  • DM199Drug

    A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety as Assessed by Incidence, Severity and Causality of AEsTime frame: From initial dose (Day 1) through Day 104
  2. Estimated Glomerular Filtration Rate (eGFR), Change From BaselineTime frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, and 16
  3. Urine Albumin to Creatinine Ratio (UACR), Change From BaselineTime frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, and 16
  4. Systolic Blood Pressure, Change From BaselineTime frame: Baseline, Day 4 through Day 95
  5. Diastolic Blood Pressure, Change From BaselineTime frame: Baseline, Day 4 through Day 95
  6. Urine KLK1 Concentration Pre and Post DM199 AdministrationTime frame: Baseline through Day 104
  7. Plasma KLK1 Concentration Pre and Post DM199 AdministrationTime frame: Baseline through Day 104

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Aventiv Research

    Mesa, Arizona

  • Amicis Research Center

    Granada Hills, California

  • Amicis Reserch Center

    Granada Hills, California

  • IMD Clinical Trials Inc

    Los Angeles, California

  • Innovative Healthcare Institute

    Coral Springs, Florida

  • Elixia at Florida Kidney Physicians-SE

    Fort Lauderdale, Florida

  • Pines Clinical Research-Hollywood

    Hollywood, Florida

  • Elixia at Florida Kidney Physicians

    Temple Terrace, Florida

  • Boise Kidney & Hypertension Institute

    Meridian, Idaho

  • Research by Design LLC

    Chicago, Illinois

  • New Orleans Center for Clinical Research, an AMR Company

    New Orleans, Louisiana

  • Elixia At Clinical Renal Associates

    Upland, Pennsylvania

  • Nephrotex Research Group, LLC

    Dallas, Texas

  • RDRI

    DeSoto, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.